Ticagrelor

ATR serine/threonine kinase ; Homo sapiens







1 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34736855 Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorbâ„¢-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. 2022 Mar 2